^
    1d
    Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
    New P1 trial
    1d
    CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Jan 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    1d
    Digital Intervention for the Modification of Lifestyles (iGame) (clinicaltrials.gov)
    P=N/A, N=48, Completed, University of Malaga | Enrolling by invitation --> Completed
    Trial completion
    1d
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=1800, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)
    1d
    PM534 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=145, Recruiting, PharmaMar | N=45 --> 145
    Enrollment change
    |
    ALK (Anaplastic lymphoma kinase)
    1d
    Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    1d
    BEND-MBEC: Plant-Based Nutrition for Breast or Endometrial Cancer (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, University of Rochester | Trial completion date: Dec 2029 --> Dec 2030 | Initiation date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2028 --> Dec 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    1d
    A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=596, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • trastuzumab brengitecan (BL-M07D1)
    1d
    THRIVE-65: TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=270, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2027 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    1d
    Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters) (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, Virginia Commonwealth University | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    1d
    Telerehabilitation in Oncology Patients (clinicaltrials.gov)
    P=N/A, N=30, Completed, University of Malaga | Recruiting --> Completed
    Trial completion
    1d
    Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout® (clinicaltrials.gov)
    P=N/A, N=204, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Aug 2026 | Trial primary completion date: Mar 2026 --> Aug 2026
    Trial completion date • Trial primary completion date